Regular Session
Government Affairs & Regulatory Compliance Analysis
HB4783 mandates the Health and Human Services Commission (HHSC) to establish statewide "saturation goals" for opioid antagonists, effectively defining the state's procurement strategy for the next biennium. While the direct reporting burden falls on state agencies, vendors and contractors in the pharmaceutical supply chain must prepare for granular data requests to support the state's mandatory "needs assessment.
Rep. Gary Vandeaver·House Bill·Regular Session
This legislation has regulatory implications for the following Texas businesses and organizations:
Standard regulatory changes (effective 2025-06-20). Review during normal business planning.
Affected business types:
lowMinimal cost impact anticipated.
JD Key Consulting provides government affairs and regulatory strategy services. We help businesses navigate Texas agencies, understand legislative impacts, and advocate for their interests.
JD Key Consulting provides strategic guidance on Texas regulatory compliance and legislative impact for your business.
Key implementation requirements and action items for compliance with this legislation
The statute requires HHSC to determine a "Statewide Saturation Goal" and identify "Insufficiencies in Current Supply," but fails to define the metrics for either.
JD Key Consulting specializes in Texas regulatory compliance strategy. Work directly with James Dickey—former Chairman of the Republican Party of Texas—to understand this bill's impact on your operations and develop an actionable compliance plan.
Schedule a ConsultationInformation presented is for general knowledge only and is provided without warranty, express or implied. Consult qualified government affairs professionals and legal counsel before making compliance decisions.
This bill's path through the Texas Legislature
Explore more bills from this author and on related topics
Common questions about HB4783
HB4783 mandates the Health and Human Services Commission (HHSC) to establish statewide "saturation goals" for opioid antagonists, effectively defining the state's procurement strategy for the next biennium. While the direct reporting burden falls on state agencies, vendors and contractors in the pharmaceutical supply chain must prepare for granular data requests to support the state's mandatory "needs assessment.
HB4783 was authored by Texas Representative Gary Vandeaver during the Regular Session.
HB4783 was signed into law by Governor Greg Abbott on June 20, 2025.
HB4783 is enforced by Health and Human Services Commission (HHSC).
The regulatory priority for HB4783 is rated as "low". Businesses and organizations should review the legislation to understand potential impacts.
The cost impact of HB4783 is estimated as "low". This may vary based on industry and implementation requirements.
HB4783 addresses topics including alcoholism & drug abuse, crimes, crimes--drugs, state agencies, boards & commissions and health & human services commission.
Key dates for HB4783: Effective date is 2025-06-20. Consult with legal counsel regarding applicability.
HB4783 primarily affects healthcare providers and medical facilities. These businesses should review the legislation with their legal and compliance teams to understand potential impacts.
JD Key Consulting is an Austin, Texas-based government affairs firm led by James Dickey, former Chairman of the Republican Party of Texas. We specialize in Texas regulatory compliance and legislative strategy for data centers, energy, banking, and manufacturing.
